Compare A O Smith Corp (AOS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
A O Smith Corp vs TG Therapeutics Inc — how do they compare? A O Smith Corp trades at $61 (market cap $8.33B), while TG Therapeutics Inc trades at $56.69 (market cap $8.74B). The key difference: A O Smith Corp and TG Therapeutics Inc are close in size by market cap, and A O Smith Corp pays a 2.35% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AOS | TGTX | |
|---|---|---|
Market Cap | $8.33B | $8.74B |
Sector | Industrials | Health |
52-Week High | $80.47 | $59.06 |
52-Week Low | $55.78 | $26.39 |
Enterprise Value | $8.78B | $8.98B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
A.O. Smith (AOS) trades at $60.44, up 2.41% today, with a bearish technical signal despite recent leadership changes. The company reported mixed Q1 2026 earnings, missing EPS estimates at $0.85 versus $0.94 expected, while maintaining solid profitability with a 13.84% net margin. Cash flow trends show improving operations, and the stock offers a dividend with a recent $0.36 payout announced.
The outlook is cautious due to earnings volatility and bearish technicals, but valuation appears reasonable with a P/E of 16.12. Risks include China market weakness and competitive pressures, while analyst consensus leans hold with a $68 price target suggesting modest upside potential from current levels.
TG Therapeutics (TGTX) trades at $57.12, down 3.28% on the day, amid mixed technical signals. The stock exhibits strong profitability with a net income margin of 65.95% and robust revenue growth, reaching $616.29 million in 2025. Recent positive news includes the initiation of a Phase II trial for Briumvi in schizophrenia and strong sales momentum, though recent quarterly EPS results have missed expectations. The technical outlook is bullish based on moving averages, but oscillators show bearish pressure with RSI levels indicating potential overbought conditions.
The investment outlook for TGTX is supported by strong analyst sentiment with 84.62% buy ratings and a consensus price target of $45.00, though the current price exceeds this target. Key opportunities include pipeline expansion and rising Briumvi demand, but risks involve clinical trial outcomes, competitive pressures, and cash flow volatility. Investors should weigh the high valuation multiples against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About A O Smith Corp
A.O. Smith Corporation manufactures and markets comprehensive lines of residential and commercial gas, gas tankless, and electric water heaters. Supplementary products include water heating equipment, condensing and noncondensing boilers, and water system tanks. The company's two operating segments are by geographic region: North America (majority of total revenue) and the Rest of the World. A material portion of sales in North America derive from replacing existing products, and the company utilizes a wholesale distribution channel and multiple selling locations. The Rest of the World segment sells primarily to Asian countries and operates sales offices to expand distribution and market its product portfolio.
Read more on AOS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
